+

WO2003007798A3 - Ophthalmic use of 5 fluorourcil - Google Patents

Ophthalmic use of 5 fluorourcil Download PDF

Info

Publication number
WO2003007798A3
WO2003007798A3 PCT/US2002/022860 US0222860W WO03007798A3 WO 2003007798 A3 WO2003007798 A3 WO 2003007798A3 US 0222860 W US0222860 W US 0222860W WO 03007798 A3 WO03007798 A3 WO 03007798A3
Authority
WO
WIPO (PCT)
Prior art keywords
living subject
fibroblastic
angiogenic
immunosuppressive
neoplastic
Prior art date
Application number
PCT/US2002/022860
Other languages
French (fr)
Other versions
WO2003007798A2 (en
Inventor
Stephen Warren
Steven Hamilton
Original Assignee
Iomed Inc
Stephen Warren
Steven Hamilton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iomed Inc, Stephen Warren, Steven Hamilton filed Critical Iomed Inc
Priority to EP02747054A priority Critical patent/EP1418919A4/en
Priority to JP2003513412A priority patent/JP2004535462A/en
Priority to AU2002316724A priority patent/AU2002316724A1/en
Publication of WO2003007798A2 publication Critical patent/WO2003007798A2/en
Publication of WO2003007798A3 publication Critical patent/WO2003007798A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a 5' fluorouracil based medicament, wherein the 5' fluorouracil based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the 5' fluorouracil based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.
PCT/US2002/022860 2001-07-20 2002-07-19 Ophthalmic use of 5 fluorourcil WO2003007798A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02747054A EP1418919A4 (en) 2001-07-20 2002-07-19 The use of 5 fluorourcil, delivered by inotophoresis as an inhibitor of cell proliferation in the eye, bulbar and palpebral conjunctiva, eyelid, peri-orbital soft tissues and skin
JP2003513412A JP2004535462A (en) 2001-07-20 2002-07-19 Use of 5-fluorouracil delivered by iontophoresis as an inhibitor of cell proliferation of the eye, bulbar conjunctiva, eyelid conjunctiva, eyelid, periorbital soft tissue and skin.
AU2002316724A AU2002316724A1 (en) 2001-07-20 2002-07-19 Ophthalmic use of 5 fluorourcil

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30678801P 2001-07-20 2001-07-20
US60/306,788 2001-07-20

Publications (2)

Publication Number Publication Date
WO2003007798A2 WO2003007798A2 (en) 2003-01-30
WO2003007798A3 true WO2003007798A3 (en) 2003-06-19

Family

ID=23186840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022860 WO2003007798A2 (en) 2001-07-20 2002-07-19 Ophthalmic use of 5 fluorourcil

Country Status (4)

Country Link
EP (1) EP1418919A4 (en)
JP (1) JP2004535462A (en)
AU (1) AU2002316724A1 (en)
WO (1) WO2003007798A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2889024B2 (en) * 1991-08-28 1999-05-10 帝人株式会社 Equipment for iontophoresis
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
FR2773320B1 (en) * 1998-01-05 2000-03-03 Optisinvest DEVICE FOR INTRAOCULAR TRANSFER OF ACTIVE PRODUCTS BY IONTOPHORESIS
IL123290A (en) * 1998-02-13 2001-12-23 Hadasit Med Res Service Iontophoretic device
WO2000051620A1 (en) * 1999-03-02 2000-09-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
WO2003007961A1 (en) * 2001-07-20 2003-01-30 Iomed, Inc. Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1418919A4 *

Also Published As

Publication number Publication date
JP2004535462A (en) 2004-11-25
AU2002316724A1 (en) 2003-03-03
WO2003007798A2 (en) 2003-01-30
EP1418919A4 (en) 2007-06-13
EP1418919A2 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
DK1574209T3 (en) Procedure for the treatment of ophthalmic diseases
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
GB0222827D0 (en) Contact lens for correcting myopia and/or astigmatism
DE60030995D1 (en) IRIS DETECTION AND TRACKING FOR EYE TREATMENT
ZA957633B (en) Corneal template and surgical procedure for refractive vision correction.
EP2319527A3 (en) BAFF, inhibitors thereof and their use in the modulation of the B-cell response
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
DE69417538D1 (en) MALEIC ACID COPOLYMER, METHOD FOR THE PRODUCTION AND USE THEREOF
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
AU6391000A (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
NO994165D0 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
WO2006017822A3 (en) Quinazoline derivatives and their use in the treatment of thrombocythemia
AU2002331606A1 (en) Non-invasive ocular assessment method and associated apparatus
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
EP1558266A4 (en) Treatment for reactive arthritis or bursitis
AU2003286555A1 (en) Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2004018648A3 (en) Methods for treating patients and identifying therapeutics
WO2004028451A3 (en) β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA
WO2003007798A3 (en) Ophthalmic use of 5 fluorourcil
AU2495697A (en) Method of enhancing cognition
EP1645285A3 (en) Therapeutical use of anti-mag antibody for the treatment of ischemic stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003513412

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002747054

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002747054

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载